Merck Sees $1.6 Million Bullish Call Activity as Stock Trades Near 52-Week Highs

By TrendSpider Editor

A single unusual options contract on Merck & Company, Inc. (MRK) has caught the attention of traders Thursday, with a $1,596,000 premium call purchase signaling notable bullish conviction from a large market participant. The stock is currently trading at $149.565, up 1.50% on the session, and si

Merck Sees $1.6 Million Bullish Call Activity as Stock Trades Near 52-Week Highs

A single unusual options contract on Merck & Company, Inc. (MRK) has caught the attention of traders Thursday, with a $1,596,000 premium call purchase signaling notable bullish conviction from a large market participant. The stock is currently trading at $149.565, up 1.50% on the session, and sits comfortably in the upper range of its 52-week band of $82.035 to $156.9199. The positioning of this trade well in the money suggests a sophisticated player is making a high-confidence directional bet on MRK heading into 2027.

Key Drivers of the MRK Stock Move

• Main Catalyst: A single unusual call contract was flagged on MRK, carrying $1,596,000 in total premium. The contract targets the $140 strike expiring June 17, 2027, with 700 contracts traded against an open interest ratio of 112%, indicating this flow exceeded all existing open interest at that strike and represents fresh, aggressive positioning.
• Bull Case: The $140 strike call is currently in the money given MRK's price of $149.565, meaning the buyer has immediate intrinsic value and is paying a rich premium for extended upside exposure through mid-2027. The open interest ratio of 112% confirms this is not a hedge recycled from existing positioning but entirely new directional flow. With the stock already up 1.50% today, the tape and the options market are aligned to the upside.
• Bear Case: MRK is trading at $149.565, within striking distance of its 52-week high of $156.9199, which may present a technical ceiling. The stock has also spent time near the lower end of its 52-week range at $82.035, illustrating meaningful historical volatility. A reversal from current levels could quickly erode the intrinsic value built into the $140 strike call, putting the $1,596,000 premium at risk.

The forward setup for MRK appears constructive based on today's options activity. A single participant deploying over $1.5 million in premium into a June 2027 expiry suggests a longer-term thesis is at play, not a short-term tactical trade. The open interest ratio breaching 112% is a meaningful signal that this strike was not previously on the market's radar at scale. Merck continues to operate in a complex pharmaceutical environment where pipeline developments, pricing dynamics, and patent timelines drive longer-duration positioning of exactly this kind. The extended expiry through June 2027 gives the trade room to absorb near-term noise while capturing any potential catalyst between now and then.

MRK Unusual Options Activity

• Type: Call | Strike: $140 | Expiry: June 17, 2027 | Volume: 700 contracts | Open Interest Ratio: 112% (in the money) | Premium: $1,596,000

This is the only unusual contract flagged on MRK today, making it a concentrated, high-conviction trade rather than a broader sweep pattern. The in-the-money status of the $140 strike relative to the current price of $149.565 means the buyer is paying for both intrinsic and time value, underscoring confidence in continued upside through mid-2027.

MRK Seasonality

Mid-October has historically been an active period for pharmaceutical names as the sector enters the final stretch of the fiscal year, with pipeline updates and conference season often serving as near-term catalysts. A June 2027 expiry would also capture Merck's typical late-spring conference cycle, a period that has historically produced meaningful price movement for large-cap pharma.

MRK Relative Performance

MRK is up 1.50% on the session and is trading at $149.565, within approximately 4.7% of its 52-week high of $156.9199. The stock has recovered substantially from its 52-week low of $82.035, representing an advance of more than 82% from that trough. Today's price action, combined with fresh in-the-money call positioning, suggests MRK is outperforming on a relative basis within the large-cap pharmaceutical space as of this session.